QT IMAGING HOLDINGS, INC. (QTI)

QT Imaging Holdings is a publicly traded medical device company focused on transforming breast imaging through advanced ultrasound technology. Since its founding in 2012, the company has developed the QTI Breast Acoustic CT™ Scanner—an FDA-cleared system that produces three-dimensional, sub-millimeter resolution images of breast tissue using transmission and reflection ultrasound, without ionizing radiation, painful compression, or contrast agents. The company represents a shift in diagnostic imaging strategy: rather than attempting to replace or compete directly with mammography, QT Imaging targets the unmet diagnostic need for women with dense breast tissue and others for whom conventional imaging modalities prove inadequate or uncomfortable.

The underlying innovation centers on quantitative ultrasound tomography, a technique that leverages lower-frequency sound waves to capture volumetric acoustic data of the breast. This raw data becomes the foundation for computational analysis, allowing radiologists to extract quantitative biomarkers that reveal tissue properties with precision. The system does not compress the breast, eliminates radiation exposure, and avoids the need for contrast injections—a meaningful difference in patient experience, particularly for younger women, those with implants, or patients who cannot tolerate conventional MRI exams. The company’s positioning explicitly acknowledges that its scanner fills a specific diagnostic gap rather than serving as a universal mammography replacement.

Operationally, QT Imaging has undergone a notable transformation in recent years. What began as a hardware-centric startup has evolved into a platform company combining physical scanners, proprietary software, and cloud-based artificial intelligence. The shift reflects a strategic decision to expand beyond equipment sales into recurring-revenue services and biomarker analytics. Revenue growth has been substantial: the company generated $18.9 million in 2025, up from $4.9 million in 2024, representing 288% year-over-year growth. This acceleration was driven by the shipment of 40 scanners across distribution agreements. In the first quarter of 2026, revenue reached $6.5 million from 13 unit shipments, and management has guided toward approximately $39 million in full-year 2026 revenue, incorporating contracted domestic shipments and initial contributions from the company’s QTI Cloud software-as-a-service offering.

The company also achieved a significant regulatory milestone in early 2026 when the American Medical Association assigned a Category III Current Procedural Terminology code for 3D breast ultrasound tomography. This coding designation is a prerequisite for insurance reimbursement in the United States, representing a critical step toward commercial adoption and recurring revenues from diagnostic scanning services. Prior to this, the company operated primarily on scanner hardware sales; the CPT code opens pathways for providers to bill imaging procedures, potentially creating a more stable revenue stream.

The 2026 public offering raised approximately $10 million in gross proceeds and followed the company’s January 2026 uplisting from the OTCQB Venture Market to the NASDAQ Capital Market under the ticker QTI—a significant validation event for a medical device company still in early commercial deployment. The uplisting reflects increasing institutional interest and tighter liquidity, allowing the company to access broader investor bases and capital markets. Cash on hand at year-end 2025 stood at $10.5 million, up substantially from $1.2 million a year prior, bolstering the balance sheet for continued manufacturing and market expansion.

Financially, the company remains unprofitable on a net income basis, recording a 2025 net loss of $21.1 million. However, this is typical for early-stage medical device manufacturers ramping production and building distribution networks. Gross margin stood at 45% for the full year 2025, with Q4 2025 at 38%, reflecting the combination of scanner hardware sales and software licensing. The cost structure typical of manufacturing—tooling, regulatory compliance, clinical validation, and capital-intensive production—explains the path to profitability being measured in years rather than quarters.

Competitively, QT Imaging operates in the broader medical imaging device sector where it faces established and emerging rivals. Major players in breast imaging include companies like Butterfly Network, which commercializes handheld ultrasound systems, and other emerging diagnostic imaging startups. The differentiation for QT Imaging lies in volumetric imaging resolution, quantitative biomarker extraction, and the elimination of compression and radiation. However, the breast imaging market remains dominated by traditional mammography networks, institutional inertia, and established relationships between hospitals, radiologists, and incumbent equipment vendors. Gaining adoption requires not only technological superiority but also reimbursement clarity, clinical evidence of diagnostic value, and integration into clinical workflows.

Market risks are material. The company faces regulatory and clinical hurdles: while FDA-cleared, the system must prove its diagnostic value in peer-reviewed clinical studies to drive adoption. Reimbursement rates, once codes are assigned, will determine the economic viability of scanning as a service. The capital intensity of the business means the company must execute on deployment targets and gross margin expansion to avoid cash depletion. Additionally, larger medical device manufacturers or diagnostic imaging platforms could accelerate competing technologies or acquire similar capabilities, creating competitive pressure. The market opportunity for advanced breast imaging is genuine and growing, driven by increased awareness of dense breast tissue risks and rising demand for non-invasive diagnostic options, but commercial success is far from assured.

To evaluate QT Imaging’s progress, investors and researchers should monitor quarterly scanner shipments, scanner placements in key markets (particularly in Saudi Arabia and the UAE, where the company has distribution agreements), reimbursement expansion beyond the initial Category III CPT code, gross margin trends as production scales, and clinical publications validating diagnostic biomarkers. The company’s 10-K filings with the SEC provide detailed financial statements, revenue segmentation, and risk disclosures. Management’s execution on the 2026 revenue guidance and sustained gross margins will be key indicators of whether the technology can transition from a specialized innovation into a sustainable, profitable business.